European regulators accept FibroGen's anemia drug for review; Passage Bio's lead gene therapy gets more love from the FDA
→ It’s approved in China and Japan, the FDA plans to make its decision by December and now the EMA has accepted FibroGen‘s anemia …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
